Whereas GLP-1 medication resembling Wegovy and Ozempic at the moment are being broadly championed and broadly used, a number of research are revealing some doubtlessly worrying uncomfortable side effects – together with new analysis that appears intimately at associated imaginative and prescient loss.
These medicines are so named due to how they mimic the results of the glucagon-like peptide-1 (GLP-1) hormone to suppress urge for food, assist digestion, and regulate blood sugar. They have been extensively prescribed to assist with weight reduction and handle diabetes.
Nevertheless, reviews of eyesight issues associated to GLP-1 medication and their energetic ingredient, semaglutide, are on the rise, prompting medicines regulators within the UK and Europe to evaluation the dangers based mostly on accessible information.
On this new examine, a workforce from universities throughout Canada analyzed information of hostile occasions collected by the US Meals and Drug Administration (FDA) over 7 years, 2017-2024, and seemed for instances of ischemic optic neuropathy (ION).
The uncommon situation may cause sudden and full imaginative and prescient loss on account of a scarcity of blood circulation to the optic nerve – and it may be everlasting in some instances.
The researchers needed to see what number of instances of ION occurred in folks taking totally different semaglutide formulations: Wegovy (for weight reduction), Ozempic (for sort 2 diabetes), and Rybelsus (for sort 2 diabetes).
“These findings lengthen our prior international evaluation and, whereas earlier research recognized solely an agent-specific affiliation, this examine offers the primary proof of a formulation- and dose-dependent ION threat, with the strongest affiliation noticed for Wegovy,” write the researchers of their printed paper.
The statistical evaluation deployed by the workforce discovered that the chances of a Wegovy-related ION criticism have been nearly 5 occasions increased than with Ozempic, whereas no clear relationship was discovered between Rybelsus and ION.
That is a stark distinction, however it’s essential to place the numbers into context. The FDA database the researchers analyzed included greater than 30 million so-called hostile occasions, and of those, there have been a complete of 28 instances linking Wegovy to ION and 47 instances linking Ozempic to ION.
Whereas that Ozempic quantity is increased, it has been prescribed for lots longer than Wegovy. Even so, the researchers discovered the strongest ION sign with Wegovy, and this persevered after adjusting for demographic elements resembling age and intercourse: The chances of ION amongst Wegovy customers have been 4.74 occasions increased than with Ozempic, based mostly on reported instances.
There was a transparent distinction between the sexes, too: Males taking semaglutide of any sort have been about 3 times extra more likely to report a case of ION than girls utilizing GLP-1 medication.
Whereas these outcomes are associations from one explicit FDA database – not threat estimates for the overall, international inhabitants prescribed semaglutide – they’re nonetheless regarding to consultants who say additional analysis is critical.
“These findings spotlight a possible dose-dependent security concern that warrants pressing potential analysis to information prescribing and regulatory coverage,” the researchers write.
The workforce did not study why a hyperlink between GLP-1 medication and imaginative and prescient loss may exist on this examine, however they’ve a couple of concepts. It is potential that Wegovy, which has been authorized to be used at increased doses than different GLP-1 medication, could decrease blood stress, maybe decreasing blood provide to the attention.
That is a speculation that additional analysis can examine. Within the meantime, scientists are constructing a posh image of GLP-1medications. In addition to their main results, they’ve been linked with a bunch of different organic penalties, from diminished most cancers threat to a larger chance of despair.
In a linked commentary, researchers from the College of Southampton within the UK (who weren’t concerned within the examine) talk about balancing the pressing want for anti-obesity methods with the equally pressing want to verify therapies are secure.
Associated: Ozempic-Like Medicine Could Enhance Danger of Bone And Joint Circumstances
“Additional research offering nuanced data of this sort are subsequently warranted,” they conclude, “for higher understanding of anti-obesity medicine results within the eye, particularly given their rising utilization.”
The analysis has been printed within the British Journal of Ophthalmology.
